Welcome to our dedicated page for Genmab news (Ticker: GMAB), a resource for investors and traders seeking the latest updates and insights on Genmab stock.
Genmab A/S (GMAB) generates frequent news flow as an international biotechnology company focused on antibody medicines for cancer and other serious diseases. Company announcements highlight advances in its antibody platforms, late‑stage clinical programs, regulatory milestones and corporate transactions, offering investors and observers a detailed view of how its science translates into clinical and commercial progress.
Recent news has emphasized the expanding clinical profile of epcoritamab (EPKINLY), an IgG1‑bispecific antibody created using Genmab’s DuoBody technology. Genmab regularly reports data from Phase 1b/2 and Phase 3 trials in diffuse large B‑cell lymphoma, follicular lymphoma and Richter transformation, including monotherapy and combination regimens with standard treatments such as R‑CHOP, R‑mini‑CHOP, rituximab and lenalidomide, and bendamustine plus rituximab. These updates often include response rates, survival outcomes and safety findings from major oncology congresses.
News coverage also includes developments in Genmab’s wholly owned pipeline, such as updated data for rinatabart sesutecan (Rina‑S) in advanced endometrial cancer and the expansion of its clinical program into Phase 3 trials. Corporate strategy items, including the planned acquisition and subsequent tender offer for Merus N.V. to add petosemtamab to the portfolio, feature prominently in company announcements and SEC‑related communications.
In addition, Genmab reports on initiatives that shape how it conducts research and development, such as its partnership with Anthropic to deploy Claude‑powered agentic AI solutions to support clinical development operations. Visitors to this GMAB news page can review these company announcements, trial readouts, regulatory updates and transaction disclosures to follow how Genmab’s antibody platforms, collaborations and late‑stage assets evolve over time.
Genmab A/S (NASDAQ: GMAB) announced promising results from the EPCORE™ NHL-1 phase 2 trial of epcoritamab for relapsed/refractory large B-cell lymphoma (LBCL). With a total patient population of 157, the study reported an overall response rate (ORR) of 63% and a complete response (CR) of 39%. Notably, CAR T-naïve patients exhibited a 69% ORR, while those previously treated with CAR T had a 54% ORR. Epcoritamab demonstrated a manageable safety profile, with treatment-emergent adverse events primarily occurring in the initial treatment weeks. Results were showcased at the EHA Annual Congress.
Genmab and Seagen presented interim results from the Phase 1b/2 innovaTV 205 trial on June 6, 2022, indicating a 41% objective response rate (ORR) in patients with recurrent or metastatic cervical cancer treated with tisotumab vedotin and pembrolizumab. This study highlights a median progression-free survival of 5.3 months and notable durability of response. Common treatment-related adverse events included alopecia and diarrhea. A new web-based tool was introduced to identify areas needing cervical cancer intervention, reflecting the companies' commitment to addressing healthcare disparities.
Seagen and Genmab have announced interim results from the innovaTV 205 trial, revealing a 41% objective response rate (ORR) for tisotumab vedotin in combination with pembrolizumab among patients with recurrent or metastatic cervical cancer (r/mCC). The data, presented at ASCO 2022, also shows a median progression-free survival of 5.3 months. The trial included 33 patients, with 25% achieving partial responses. Adverse events were primarily manageable, with common occurrences including alopecia and diarrhea. The companies will continue to explore tisotumab vedotin in combination therapies to address unmet needs.
Genmab (Nasdaq: GMAB) announced the acceptance of multiple abstracts for presentation at the 2022 ASCO Annual Meeting, showcasing investigational medicines from its pipeline. Key highlights include data from the phase 1b/2 EPCORE™ NHL-2 trial evaluating epcoritamab (DuoBody-CD3xCD20) in B-cell non-Hodgkin lymphoma and an oral presentation of tisotumab vedotin in recurrent or metastatic cervical cancer. The findings reinforce Genmab's commitment to delivering innovative therapies, with partnerships alongside AbbVie (ABBV) and Seagen (SGEN).
Genmab A/S (Nasdaq: GMAB) announced that multiple abstracts showcasing preliminary efficacy and safety findings of epcoritamab (DuoBody-CD3xCD20) will be presented at the European Hematology Association (EHA) Annual Congress in Vienna, Austria, from June 9-12. The studies include various clinical trials, focusing on B-cell non-Hodgkin lymphoma treatments. Epcoritamab is co-developed with AbbVie (NYSE: ABBV), underscoring a commitment to deliver new treatment options for patients.
AbbVie and Genmab announced topline results from the EPCORE™ NHL-1 clinical trial for epcoritamab (DuoBody®-CD3xCD20), targeting relapsed/refractory large B-cell lymphoma (LBCL). The trial involved 157 patients with a confirmed overall response rate (ORR) of 63.1% and a median duration of response (DOR) of 12 months. Common adverse events included cytokine release syndrome (49.7%) and neutropenia (21.7%). The companies plan to engage global regulatory authorities and present data at a future medical conference.
Genmab (NASDAQ: GMAB) and AbbVie (NYSE: ABBV) announced positive topline results from the EPCORE™ NHL-1 clinical trial for epcoritamab, a bispecific antibody targeting large B-cell lymphoma (LBCL). The trial, involving 157 patients, demonstrated an overall response rate (ORR) of 63.1%, surpassing efficacy benchmarks, with a median duration of response (DOR) of 12 months. The companies will engage global regulatory authorities to determine next steps and plan to present detailed data at an upcoming medical meeting.
Genmab A/S (NASDAQ: GMAB) announced that the FDA has granted orphan-drug designation to epcoritamab (DuoBody®-CD3xCD20) for treating follicular lymphoma (FL). This designation aids the development of treatments for rare diseases affecting fewer than 200,000 people annually. FL is the second most common form of non-Hodgkin’s lymphoma, impacting approximately 2.7 per 100,000 people in the U.S. Epcoritamab is currently in multiple clinical trials, providing hope for patients who are refractory to conventional therapies.
Genmab A/S (NASDAQ: GMAB) and Seagen Inc. (NASDAQ: SGEN) announced preliminary results from the innovaTV 207 phase 2 trial of tisotumab vedotin (TIVDAK®) for squamous cell carcinoma of the head and neck. Of 31 patients treated, a 16% objective response rate was observed. Secondary endpoints showed a disease control rate of 58.1% and median progression-free survival of 4.2 months. Safety data indicated a manageable profile, with 67.7% experiencing Grade ≥3 adverse events. The findings will be presented at the ASTRO 2022 symposium on February 25.
Seagen and Genmab will present preliminary data from the innovaTV 207 phase 2 trial of tisotumab vedotin (TIVDAK) for patients with squamous cell carcinoma of the head and neck at the ASTRO 2022 symposium. Results indicate a 16% confirmed objective response rate, with 58.1% disease control rate and a median progression-free survival of 4.2 months. Noteworthy adverse events included Grade ≥3 treatment-emergent adverse events in 67.7% of patients. The data underscores the potential of tisotumab vedotin in treating this high-need patient group, with ongoing trials planned.